Key Drivers
- Strong Cash Flow
- Liquidity Pressure
- Rich Valuation
AIAI Summary
CHE should now be viewed as a two-engine story rather than a simple defensive healthcare name: VITAS is the only real growth driver and must keep outpacing Roto-Rooter's margin erosion and rising leverage to justify an already-full valuation, so the key takeaway is that execution at VITAS—not sector defensiveness—will determine whether the stock can keep working from here.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Liquidity Pressure
- •Rich Valuation
CHE remains highly profitable with strong cash generation, but weaker Q1 liquidity, higher leverage, and a premium valuation mean the stock now hinges on sustaining cash flow.
Price Behavior
Key Price Behavior Insights:
- •Higher-high trend
- •Strong rebound
- •Stretch risk
CHE has trended higher over the last month with a ~15% gain, a series of higher highs/lows, and a strong close near the top of its range, though the run-up looks stretched and could pause near $490.
Roughly 8% gain in a week since 2026-06-25 signals a sharp short-term acceleration
Sentiment & News
Key News Insights:
- •Texas expansion
- •VITAS growth
- •July earnings
Chemed's outlook is supported by Roto-Rooter's Texas expansion and VITAS growth, but inflation, tariffs and competition remain key risks ahead of its late-July earnings report.
The news is mildly supportive for Chemed shares, but the stock will likely hinge on whether upcoming earnings confirm that growth can outpace cost pressures
Similar Companies in Healthcare
Other companies in the same sector with AI ratings